According to Zacks, “Grifols, S.A., operates in the pharmaceutical-hospital sector engaged in the research, development and retailing of plasma derivates, products for intravenous therapy, clinical nutrition, diagnostic and hospital logistics systems. The Company operates its business through three divisions: Bioscience Division, Diagnostic Division and Hospital Division. The Bioscience division is engaged in the research, development, production and commercialization of plasma derivates. Diagnostic Division focuses on researching, developing, manufacturing and marketing diagnostics products for laboratory analysis, including products for Hospital Blood Banks and Transfusion Centers. Hospital Division provides non-biological products used in hospital pharmacies, surgery, nutritional support, fluid therapy and for other therapeutic uses. Grifols, S.A. is based in Barcelona, Spain. “
Other research analysts have also recently issued reports about the stock. Santander raised shares of GRIFOLS S A/S from a “hold” rating to a “buy” rating in a research note on Monday, October 28th. ValuEngine raised GRIFOLS S A/S from a “sell” rating to a “hold” rating in a research note on Wednesday, October 2nd. BidaskClub raised GRIFOLS S A/S from a “sell” rating to a “hold” rating in a research note on Wednesday. Finally, Berenberg Bank upgraded GRIFOLS S A/S to a “buy” rating in a report on Wednesday, October 30th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $20.75.
A number of hedge funds have recently made changes to their positions in GRFS. Thomas White International Ltd. purchased a new position in GRIFOLS S A/S in the 2nd quarter valued at about $84,000. Assetmark Inc. lifted its stake in shares of GRIFOLS S A/S by 453.8% during the second quarter. Assetmark Inc. now owns 6,363 shares of the biotechnology company’s stock valued at $134,000 after buying an additional 5,214 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its position in GRIFOLS S A/S by 24.2% during the second quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 7,818 shares of the biotechnology company’s stock worth $165,000 after acquiring an additional 1,522 shares during the last quarter. First Light Asset Management LLC acquired a new stake in GRIFOLS S A/S during the second quarter worth approximately $215,000. Finally, Blackhawk Capital Partners LLC. acquired a new stake in GRIFOLS S A/S during the second quarter worth approximately $254,000. 18.18% of the stock is owned by hedge funds and other institutional investors.
About GRIFOLS S A/S
Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes a range of biological medicines on plasma derived proteins worldwide. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use; and sells and distributes end products.
See Also: What is the Coverage Ratio?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for GRIFOLS S A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRIFOLS S A/S and related companies with MarketBeat.com's FREE daily email newsletter.